These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16343823)

  • 1. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
    Henderson CJ; Pass GJ; Wolf CR
    Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
    Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
    Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
    Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
    Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver.
    Mutch DM; Crespy V; Clough J; Henderson CJ; Lariani S; Mansourian R; Moulin J; Wolf CR; Williamson G
    Am J Physiol Gastrointest Liver Physiol; 2006 Jul; 291(1):G63-72. PubMed ID: 16455785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice.
    Wang XJ; Chamberlain M; Vassieva O; Henderson CJ; Wolf CR
    Biochem J; 2005 Jun; 388(Pt 3):857-67. PubMed ID: 15717863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
    Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
    Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
    Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disruption of hepatic cytochrome p450 reductase alters mouse lipid metabolism.
    Mutch DM; Klocke B; Morrison P; Murray CA; Henderson CJ; Seifert M; Williamson G
    J Proteome Res; 2007 Oct; 6(10):3976-84. PubMed ID: 17722906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
    Huang Z; Raychowdhury MK; Waxman DJ
    Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
    Arlt VM; Poirier MC; Sykes SE; John K; Moserova M; Stiborova M; Wolf CR; Henderson CJ; Phillips DH
    Toxicol Lett; 2012 Sep; 213(2):160-6. PubMed ID: 22759596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity.
    Xue X; Gong L; Qi X; Wu Y; Xing G; Yao J; Luan Y; Xiao Y; Li Y; Wu X; Chen M; Gu J; Ren J
    Toxicol Lett; 2011 Aug; 205(1):47-54. PubMed ID: 21596114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene.
    Wu L; Gu J; Weng Y; Kluetzman K; Swiatek P; Behr M; Zhang QY; Zhuo X; Xie Q; Ding X
    Genesis; 2003 Aug; 36(4):177-81. PubMed ID: 12929087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase.
    Henderson CJ; Otto DM; Carrie D; Magnuson MA; McLaren AW; Rosewell I; Wolf CR
    J Biol Chem; 2003 Apr; 278(15):13480-6. PubMed ID: 12566435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
    Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
    Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system.
    Finn RD; McLaren AW; Carrie D; Henderson CJ; Wolf CR
    J Pharmacol Exp Ther; 2007 Jul; 322(1):40-7. PubMed ID: 17435107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
    Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
    J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome b
    Reed L; Mrizova I; Barta F; Indra R; Moserova M; Kopka K; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Arch Toxicol; 2018 Apr; 92(4):1625-1638. PubMed ID: 29368147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.